Skip to main content
Premium Trial:

Request an Annual Quote

DNA Sciences files $125 Million IPO

Jan 8- DNA Sciences has filed a $125 million initial public offering with the Securities and Exchange Commission, Reuters reported Monday.

The company said it plans to use the money to expand its studies on the role genes play in diseases such as cancer, asthma and diabetes and bolster its genetic database, and to commercialize diagnostic tests it is developing for common diseases, as well as to subscribe to genetic databases and fund corporate expenses, according to Reuters.

The company, which is to be listed on the Nasdaq, will go under the symbol DNAS. The company has not yet named the price.

DNA Sciences hired Lehman Brothers, CIBC World Markets and Dain Rauscher to manage its IPO, Reuters reported.

 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.